Want to see IN:INDOCO full AI Analyst Report?
INDOCO Stock Chart & Stats
₹228.35
-₹0.55(-0.16%)
At close: 4:00 PM EST
₹228.35
-₹0.55(-0.16%)
Day’s Range― - ―
52-Week Range₹163.70 - ₹348.10
Previous CloseN/A
Volume47.33K
Average Volume (3M)38.33K
Market Cap
₹22.57B
Enterprise Value₹31.88B
Total Cash (Recent Filing)₹231.50M
Total Debt (Recent Filing)₹9.99B
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)-12.73
Shares Outstanding92,303,604
10 Day Avg. Volume7,145
30 Day Avg. Volume38,334
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)1.55
Price to Sales (P/S)0.79
P/FCF Ratio-12.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.43
Revenue Forecast (FY)₹21.08B
Bulls Say, Bears Say
Bulls Say
Diversified Business Model (Formulations, APIs, CDMO/CMO)Indoco’s mix of branded/generic formulations, in‑house APIs and CDMO/CMO services spreads revenue across channels and geographies. This structural diversification reduces customer concentration risk, leverages manufacturing scale and provides multiple durable cash generation levers.
Consistent Revenue Growth (~10.7%)Sustained top‑line expansion (~10.7% reported) reflects underlying demand and execution in domestic and export markets. Durable revenue growth supports better capacity utilization, funds regulatory filings and pipeline investments, and underpins a medium‑term recovery plan even if margins take longer to normalize.
Sustained Gross Margin (~41%)A gross margin near 41% indicates product mix strength and manufacturing efficiency, giving Indoco a structural pricing buffer in the low‑margin generics industry. This margin base supports continued R&D and regulatory spend and gives room for operating leverage to restore profitability over time.
Bears Say
Two Consecutive Years Of Net Losses; Weak Operating MarginsTwo straight loss years and an EBIT margin near 0.8% show the company is not converting sales into sustainable operating profit. Persistent losses erode retained earnings, limit reinvestment for approvals and pipeline, and heighten vulnerability to cost or pricing shocks over multiple quarters.
Rising Leverage Reduces FlexibilityLeverage rising to ~1.16 meaningfully reduces financial flexibility and increases interest expense exposure. Higher debt constrains capital allocation for R&D, regulatory filings and potential M&A, and elevates solvency risk if profitability does not return, limiting strategic options over the medium term.
Deeply Negative Free Cash Flow; Weak Cash GenerationLarge negative free cash flow while operating cash is minimal forces reliance on external financing to fund capex and working capital. This structural cash shortfall raises liquidity risk, limits ability to self‑fund growth or regulatory investments, and pressures balance sheet resilience over coming quarters.
Indoco Remedies Limited News
INDOCO FAQ
What was Indoco Remedies Limited’s price range in the past 12 months?
Indoco Remedies Limited lowest stock price was ₹163.70 and its highest was ₹348.10 in the past 12 months.
What is Indoco Remedies Limited’s market cap?
Indoco Remedies Limited’s market cap is ₹22.57B.
When is Indoco Remedies Limited’s upcoming earnings report date?
Indoco Remedies Limited’s upcoming earnings report date is Jul 28, 2026 which is in 23 days.
How were Indoco Remedies Limited’s earnings last quarter?
Indoco Remedies Limited released its earnings results on May 07, 2026. The company reported -₹2.45 earnings per share for the quarter, beating the consensus estimate of -₹3.55 by ₹1.1.
Is Indoco Remedies Limited overvalued?
According to Wall Street analysts Indoco Remedies Limited’s price is currently Overvalued.
Does Indoco Remedies Limited pay dividends?
Indoco Remedies Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.08%. See more information on Indoco Remedies Limited dividends here
What is Indoco Remedies Limited’s EPS estimate?
Indoco Remedies Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indoco Remedies Limited have?
Indoco Remedies Limited has 92,303,604 shares outstanding.
What happened to Indoco Remedies Limited’s price movement after its last earnings report?
Indoco Remedies Limited reported an EPS of -₹2.45 in its last earnings report, beating expectations of -₹3.55. Following the earnings report the stock price went up 10.222%.
Which hedge fund is a major shareholder of Indoco Remedies Limited?
Currently, no hedge funds are holding shares in IN:INDOCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indoco Remedies Limited
Indoco Remedies Limited, an Indian pharmaceutical company founded in Mumbai in 1945 (originally known as Indo Continental Trading Company), operates globally, manufacturing and distributing a broad spectrum of finished drug formulations and active pharmaceutical ingredients (APIs). The company's extensive product portfolio addresses diverse therapeutic areas: Respiratory conditions: with offerings like Karvol Plus, Febrex Plus, and Tuspel. Oral and dental care (stomatologicals): including Sensodent-K, Sensoform Toothpaste, the Rexidin series, and Snowdent. Gastrointestinal ailments: featuring products such as Carmicide, Cyclopam, and Nosic. Pain relief/analgesics: exemplified by Lignox and T-lac. Ophthalmic and otic solutions: comprising items like Renolen, Dexoren – S, and the Mofloren range. Vitamins, minerals, and nutritional supplements: such as Methycal, MCBM DHA, and Apispur. Urological treatments: including Carmicide and Cital. Dermatological preparations: like Cloben G and Scabex. Anti-infective agents: represented by ATM. Blood-related therapies: such as Hemsyl. Gynecological health products: including MCBM 69 and D Chiro. Anti-haemorrhoidal treatments: with Spear. Beyond its pharmaceutical manufacturing, Indoco Remedies provides comprehensive analytical services. These include impurity profiling, particle size analysis, heavy metal analysis, polymorphism studies, compatibility and stability assessments (like extractables/leachables and lyophilization), and advanced chromatographic method development and validation. Furthermore, the company offers a suite of engineering and project management services. This covers architectural and structural design, mechanical and electrical engineering, lighting solutions, control system integration, piping design, data transfer systems, and holistic project and construction management for process facilities. Indoco Remedies serves a wide range of medical professionals, from general practitioners and pediatricians to specialized consultants like dentists, cardiologists, diabetologists, endocrinologists, gynaecologists, and ophthalmologists.
Technical Analysis
Alembic Pharmaceuticals Limited
―
Hikal Limited
―
Morepen Laboratories Limited
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―